| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VRK2 |
| Uniprot No | Q86Y07 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-508aa |
| 氨基酸序列 | MPPKRNEKYKLPIPFPEGKVLDDMEGNQWVLGKKIGSGGFGLIYLAFPTNKPEKDARHVVKVEYQENGPLFSELKFYQRVAKKDCIKKWIERKQLDYLGIPLFYGSGLTEFKGRSYRFMVMERLGIDLQKISGQNGTFKKSTVLQLGIRMLDVLEYIHENEYVHGDIKAANLLLGYKNPDQVYLADYGLSYRYCPNGNHKQYQENPRKGHNGTIEFTSLDAHKGVALSRRSDVEILGYCMLRWLCGKLPWEQNLKDPVAVQTAKTNLLDELPQSVLKWAPSGSSCCEIAQFLVCAHSLAYDEKPNYQALKKILNPHGIPLGPLDFSTKGQSINVHTPNSQKVDSQKAATKQVNKAHNRLIEKKVHSERSAESCATWKVQKEEKLIGLMNNEAAQESTRRRQKYQESQEPLNEVNSFPQKISYTQFPNSFYEPHQDFTSPDIFKKSRSPSWYKYTSTVSTGITDLESSTGLWPTISQFTLSEETNADVYYYRIIIPVLLMLVFLALFFL |
| 预测分子量 | 58,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VRK2重组蛋白的3篇参考文献示例(注：内容为模拟概括，实际文献需根据具体研究查询)：
1. **文献名称**：*"Expression and purification of recombinant human VRK2 kinase in Escherichia coli for functional studies"*
**作者**：Smith A, et al.
**摘要**：该研究描述了利用大肠杆菌表达系统高效表达并纯化人源VRK2重组蛋白的优化方法，通过亲和层析和尺寸排阻色谱获得高纯度蛋白，并验证其体外激酶活性。
2. **文献名称**：*"Structural insights into VRK2 kinase domain and its interaction with small molecules"*
**作者**：Chen L, et al.
**摘要**：通过X射线晶体学解析了重组VRK2激酶结构域的三维结构，并探究其与潜在抑制剂的结合模式，为靶向VRK2的药物设计提供依据。
3. **文献名称**：*"VRK2 recombinant protein modulates MAPK signaling pathway in glioblastoma cells"*
**作者**：Park JH, et al.
**摘要**：研究利用重组VRK2蛋白处理胶质母细胞瘤细胞，发现其通过调控MAPK信号通路影响肿瘤细胞的增殖和凋亡，提示VRK2在癌症治疗中的潜在作用。
建议通过PubMed或Web of Science以“VRK2 recombinant protein”为关键词检索最新文献获取详细信息。
**Background of VRK2 Recombinant Protein**
VRK2 (Vaccinia-related kinase 2) is a serine/threonine protein kinase belonging to the VRK family, which shares structural homology with vaccinia virus B1R kinase. It plays a role in regulating diverse cellular processes, including cell cycle progression, stress response, DNA damage repair, and apoptosis. VRK2 exists in two isoforms: VRK2A, which is membrane-associated due to a C-terminal hydrophobic domain anchoring it to the endoplasmic reticulum, and VRK2B, a shorter cytosolic variant. Dysregulation of VRK2 has been implicated in cancer, neurodegenerative diseases, and immune disorders, making it a potential therapeutic target.
Recombinant VRK2 protein is engineered in vitro using expression systems like *E. coli*, yeast, or mammalian cells. Its production involves cloning the VRK2 gene into a vector, optimizing expression conditions, and purifying the protein via affinity chromatography. The recombinant form retains kinase activity and structural integrity, enabling functional studies such as substrate phosphorylation assays, interaction mapping, and inhibitor screening.
Research using VRK2 recombinant protein has advanced understanding of its molecular mechanisms. For example, VRK2 modulates stress-activated MAPK pathways and interacts with signaling proteins like JIP1 and ATF2. In cancer, overexpression of VRK2 correlates with poor prognosis, possibly by promoting tumor cell survival under stress. In neurodegenerative contexts, VRK2 may influence neuronal homeostasis through pathways linked to ALS or Alzheimer’s disease.
Overall, VRK2 recombinant protein serves as a critical tool for dissecting its biological roles and developing targeted therapies. Its applications span basic research, drug discovery, and biomarker studies, bridging molecular insights with clinical translation.
×
